Form 8-K - Current report:
SEC Accession No. 0001140361-25-012366
Filing Date
2025-04-04
Accepted
2025-04-04 16:39:04
Documents
13
Period of Report
2025-04-02
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K ef20046946_8k.htm   iXBRL 8-K 27692
  Complete submission text file 0001140361-25-012366.txt   161945

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA ird-20250402.xsd EX-101.SCH 3976
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE ird-20250402_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ird-20250402_pre.xml EX-101.PRE 16041
15 EXTRACTED XBRL INSTANCE DOCUMENT ef20046946_8k_htm.xml XML 4051
Mailing Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709
Business Address 8 DAVIS DRIVE SUITE 220 DURHAM NC 27709 248-681-9815
Opus Genetics, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 25815459
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)